RESEARCH LETTER

Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients

ABSTRACT

Rationale Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting.

Methods Adult patients (18–75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up.

Results For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03).

Conclusions The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses.

Trial registration http://www.clinicaltrials.gov / ClinicalTrials.gov identification number: NCT01141855.

Smoking accounts for 15% of all deaths, 80% of all lung cancer deaths and is responsible for the greatest disease burden in Australia.1 In the outpatient setting, varenicline tartrate has been shown to raise the odds of quitting smoking by 2.5–3-times compared with placebo, 12-months after quitting.2,3 Of the available primary prevention initiatives, general practitioners (GPs) significantly under-use Quitline services or medications, and only 6% of patients who are encouraged to use Quitline by their GP do so.4 Abstinence from smoking, following a hospital admission, has been associated with reduced readmissions, with patients who stop smoking by the time of discharge, after 5 year follow up, having up to 31% less hospital admission bed days, 15% less outpatient visits and 50% less bed days used compared with those that continue smoking.5 Yet to our knowledge initiation of varenicline has not been evaluated in an inpatient-initiated setting, where the opportunity for a targeted secondary prevention programme combined with counselling could be used. Inpatient stays may provide (i) an opportunity to use a patient’s reflection upon their illness (ii) bedside phone to ensure initial contact with Quitline counselling service, and (iii) observation period for any medication related adverse effects. We therefore conducted a randomised, multicentre controlled clinical trial, with a 12-week treatment phase and 12-months follow-up.

Participants were recruited following admission to hospital due to a serious smoking related illness, within the disciplines of respiratory, cardiology, neurology and vascular medicine. They were aged 18–75 years, smoked at least 10 cigarettes per day over the past 12 months with a plan to quit during their hospital admission, for inPatients (STOP); superiority of 12-weeks of varenicline plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients.

Table 1 Continuous smoking abstinence at each follow-up period

<table>
<thead>
<tr>
<th>Levels of continuous abstinence</th>
<th>Varenicline</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous smoking abstinence at each follow-up period</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>2–52-weeks</td>
<td>61</td>
<td>31.1</td>
</tr>
<tr>
<td>2–26-weeks</td>
<td>78</td>
<td>39.8</td>
</tr>
<tr>
<td>2–12-weeks (EOT)</td>
<td>95</td>
<td>48.5</td>
</tr>
</tbody>
</table>

Based on intention-to-treat analysis; sample size in each arm =196. Adj, Adjusted for baseline discipline differences (cardiology, respiratory, neurology, Vascular); EOT, End of treatment.

Figure 1 Differential gap over the 52-week study period in continuous smoking abstinence between groups.
Correspondence to Kristin Veronica Carson, Clinical Practice Unit, The Basil Hetzel Research Institute for Translational Health Research, The Queen Elizabeth Hospital, DX 465154, 28 Woodville Road, Woodville South, SA 5011, Australia; kristin.carson@health.sa.gov.au

An additional data is published online only. To view this file please visit the journal online (http://dx.doi.org/10.1136/thoraxjnl-2012-202484).

Acknowledgements The authors would like to acknowledge the staff of the Queen Elizabeth Hospital, Lyell McEwin Hospital and Royal Adelaide Hospital that assisted in subject recruitment. The authors would also like to thank Pam Gluyas and Karen Boath for their assistance with subject follow-up and Rosanna McCawley and Michelle Ashley for administrative assistance.

Contributors All authors named on this manuscript fulfill the criteria of authorship, contributing to conception, design and implementation or data collection, analysis and interpretation. All named authors contributed to this manuscript through drafting the article or revising it critically for important intellectual content and give permission for this version to be published. There are no other potential authors who fulfill the above mentioned criteria and have not been included as an author.

Funding The Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, Australia.

Competing interests None.

Patient consent Obtained

Ethics approval Ethics approvals were obtained from the following committees: Human Research Ethics Committee for The Queen Elizabeth Hospital and Lyell McEwin Hospital; Application 2008012; First approved on the 14th of March 2008. Research Ethics Committee for the Royal Adelaide Hospital; Application 080520; First approved on the 18th of June 2008.

Provenance and peer review Not commissioned; internally peer reviewed.

Data sharing statement Additional data is available from the corresponding author at kristin.carson@health.sa.gov.au.

Accepted 16 August 2012
Thorax 2012;00:1–2.
doi:10.1136/thoraxjnl-2012-202484

REFERENCES


Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients


Thorax published online September 19, 2012

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2012/09/18/thoraxjnl-2012-202484

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2012/09/18/thoraxjnl-2012-202484.DC1

References
This article cites 2 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/early/2012/09/18/thoraxjnl-2012-202484#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.